Other relevant information about the company follows: The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent. Required: Answer the following questions given the information above Calculate to the following for Pharmos considering its tax rate of 25%: i. After-tax cost of Bonds ii. Cost of Equity NO EXCEL SPREADSHEETS SHOW FULL WORKINGS WITHOUT EXCEL
Other relevant information about the company follows: The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent. Required: Answer the following questions given the information above Calculate to the following for Pharmos considering its tax rate of 25%: i. After-tax cost of Bonds ii. Cost of Equity NO EXCEL SPREADSHEETS SHOW FULL WORKINGS WITHOUT EXCEL
Essentials Of Investments
11th Edition
ISBN:9781260013924
Author:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Chapter1: Investments: Background And Issues
Section: Chapter Questions
Problem 1PS
Related questions
Question
Other relevant information about the company follows:
The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent.
Required: Answer the following questions given the information above
Calculate to the following for Pharmos considering its tax rate of 25%:
i. After-tax cost of Bonds
ii.
NO EXCEL SPREADSHEETS
SHOW FULL WORKINGS WITHOUT EXCEL
![Pharmos Incorporated is a Pharmaceutical Company which is considering investing in a new
production line of portable electrocardiogram (ECG) machines for its clients who suffer from
cardiovascular diseases. The company must invest in equipment which cost $2,500,000 and falls
within a MARCS depreciation of 5-years and is expected to have a scrape value of $200,000 at|
the end of the project. Other than the equipment, the company needs to increase its cash and
cash equivalents by $100,000, increase the level of inventory by $30,000, increase accounts
receivable by $250,000 and increase account payable by $50,000 at the beginning of the
project. Pharmos Incorporated expect the project to have a life of five years. The company
would have to pay for transportation and installation of the equipment which has an invoice
price of $450,000o.
The company has already invested $75,000 in Research and Development and therefore
expects a positive impact on the demand for the new product line. Expected annual sales for
the ECG machines in the first three years are $1,200,000 and $850,000 in the following two
years. The variable costs of production are projected to be $267,000 per year in years one to
three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of
the project.
The introduction of the new line of portable ECG machines will cause a net decrease of $50,000
in profit, EACH YEAR in contribution after taxes, due to a decrease in sales of the other lines of
tester machines produced by the company. By investing in the new product line Pharmos
Incorporated would have to use a packaging machine which the company already has and will
be sold at the end of the project for $350,000 after-tax in the equipment market.](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Fdcc1a9f2-feca-4634-abfe-dd6255893ee3%2Ff6782329-b2d4-47b4-9bd5-4cd5722e37dc%2Fg86kzck_processed.jpeg&w=3840&q=75)
Transcribed Image Text:Pharmos Incorporated is a Pharmaceutical Company which is considering investing in a new
production line of portable electrocardiogram (ECG) machines for its clients who suffer from
cardiovascular diseases. The company must invest in equipment which cost $2,500,000 and falls
within a MARCS depreciation of 5-years and is expected to have a scrape value of $200,000 at|
the end of the project. Other than the equipment, the company needs to increase its cash and
cash equivalents by $100,000, increase the level of inventory by $30,000, increase accounts
receivable by $250,000 and increase account payable by $50,000 at the beginning of the
project. Pharmos Incorporated expect the project to have a life of five years. The company
would have to pay for transportation and installation of the equipment which has an invoice
price of $450,000o.
The company has already invested $75,000 in Research and Development and therefore
expects a positive impact on the demand for the new product line. Expected annual sales for
the ECG machines in the first three years are $1,200,000 and $850,000 in the following two
years. The variable costs of production are projected to be $267,000 per year in years one to
three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of
the project.
The introduction of the new line of portable ECG machines will cause a net decrease of $50,000
in profit, EACH YEAR in contribution after taxes, due to a decrease in sales of the other lines of
tester machines produced by the company. By investing in the new product line Pharmos
Incorporated would have to use a packaging machine which the company already has and will
be sold at the end of the project for $350,000 after-tax in the equipment market.
![The company will contract a new loan in the sum of $2,000,000 that is secured by
machinery and the loan has an interest rate of 6 percent. Pharmos Incorporated has also
issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually, and
matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2
percent per issue.
The company's preferred stock pays an annual dividend of 4.5 percent and is currently
selling for $60, and there are 100,000 shares outstanding.
• There are 300,000 shares of common stock outstanding, and they are currently selling
for $21 each. The beta on these shares is 0.95.](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Fdcc1a9f2-feca-4634-abfe-dd6255893ee3%2Ff6782329-b2d4-47b4-9bd5-4cd5722e37dc%2F4pced1_processed.jpeg&w=3840&q=75)
Transcribed Image Text:The company will contract a new loan in the sum of $2,000,000 that is secured by
machinery and the loan has an interest rate of 6 percent. Pharmos Incorporated has also
issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually, and
matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2
percent per issue.
The company's preferred stock pays an annual dividend of 4.5 percent and is currently
selling for $60, and there are 100,000 shares outstanding.
• There are 300,000 shares of common stock outstanding, and they are currently selling
for $21 each. The beta on these shares is 0.95.
Expert Solution
![](/static/compass_v2/shared-icons/check-mark.png)
This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
Step by step
Solved in 5 steps with 6 images
![Blurred answer](/static/compass_v2/solution-images/blurred-answer.jpg)
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.Recommended textbooks for you
![Essentials Of Investments](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781260013924/9781260013924_smallCoverImage.jpg)
Essentials Of Investments
Finance
ISBN:
9781260013924
Author:
Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:
Mcgraw-hill Education,
![FUNDAMENTALS OF CORPORATE FINANCE](https://www.bartleby.com/isbn_cover_images/9781260013962/9781260013962_smallCoverImage.gif)
![Financial Management: Theory & Practice](https://www.bartleby.com/isbn_cover_images/9781337909730/9781337909730_smallCoverImage.gif)
![Essentials Of Investments](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781260013924/9781260013924_smallCoverImage.jpg)
Essentials Of Investments
Finance
ISBN:
9781260013924
Author:
Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:
Mcgraw-hill Education,
![FUNDAMENTALS OF CORPORATE FINANCE](https://www.bartleby.com/isbn_cover_images/9781260013962/9781260013962_smallCoverImage.gif)
![Financial Management: Theory & Practice](https://www.bartleby.com/isbn_cover_images/9781337909730/9781337909730_smallCoverImage.gif)
![Foundations Of Finance](https://www.bartleby.com/isbn_cover_images/9780134897264/9780134897264_smallCoverImage.gif)
Foundations Of Finance
Finance
ISBN:
9780134897264
Author:
KEOWN, Arthur J., Martin, John D., PETTY, J. William
Publisher:
Pearson,
![Fundamentals of Financial Management (MindTap Cou…](https://www.bartleby.com/isbn_cover_images/9781337395250/9781337395250_smallCoverImage.gif)
Fundamentals of Financial Management (MindTap Cou…
Finance
ISBN:
9781337395250
Author:
Eugene F. Brigham, Joel F. Houston
Publisher:
Cengage Learning
![Corporate Finance (The Mcgraw-hill/Irwin Series i…](https://www.bartleby.com/isbn_cover_images/9780077861759/9780077861759_smallCoverImage.gif)
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Finance
ISBN:
9780077861759
Author:
Stephen A. Ross Franco Modigliani Professor of Financial Economics Professor, Randolph W Westerfield Robert R. Dockson Deans Chair in Bus. Admin., Jeffrey Jaffe, Bradford D Jordan Professor
Publisher:
McGraw-Hill Education